Edwin Fouché
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edwin Fouché has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Montagner
Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM, 31400, Toulouse, France
4 shared publications - Arnaud Polizzi
Affiliation Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP-PURPAN, UMR1331, Université de Toulouse, Toulouse, France
4 shared publications - Céline Lukowicz
Institut National de la Recherche Agronomique (INRA), UMR1331 Toxalim, F31-027 Toulouse CEDEX 3, France
4 shared publications - Hervé Guillou
Affiliation Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP-PURPAN, UMR1331, Université de Toulouse, Toulouse, France
4 shared publications - Catherine Postic
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
3 shared publications - Frédéric Lasserre
Institut National de la Recherche Agronomique (INRA), UMR1331 Toxalim, F31-027 Toulouse CEDEX 3, France
3 shared publications
Latest Publications
- Open Access
- 5 February 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-12
Opuntia cladode powders inhibit adipogenesis in 3 T3-F442A adipocytes and a high-fat-diet rat model by modifying metabolic parameters and favouring faecal fat excretion
Background: Obesity is a major public health concern worldwide. A sedentary life and a nutritional transition to processed foods and high-calorie diets are contributing factors to obesity. The demand for nutraceutical foods, such as herbal weight-loss products, which offer the potential to counteract obesity, has consequently increased. We hypothesised that Opuntia cladodes consumption could assist weight management in an obesity prevention context. Methods: This study was designed to explore the anti-adipogenic effects of lyophilised Opuntia cladode powders (OCP) in an in vitro cellular model for adipocyte differentiation and an in vivo high-fat-diet (HFD)-induced obesity rat model. Two OCP were tested, one from wild species O. streptacantha and the second from the most known species O. ficus-indica. Results: Pre-adipocytes 3 T3-F442A were treated by OCP during the differentiation process by insulin. OCP treatment impaired the differentiation in adipocytes, as supported by the decreased triglyceride content and a low glucose uptake, which remained comparable to that observed in undifferentiated controls, suggesting that an anti-adipogenic effect was exerted by OCP. Sprague–Dawley rats were fed with a normal or HFD, supplemented or not with OCP for 8 weeks. OCP treatment slightly reduced body weight gain, liver and abdominal fat weights, improved some obesity-related metabolic parameters and increased triglyceride excretion in the faeces. Taken together, these results showed that OCP might contribute to reduce adipogenesis and fat storage in a HFD context, notably by promoting the faecal excretion of fats. Conclusions: Opuntia cladodes may be used as a dietary supplement or potential therapeutic agent in diet-based therapies for weight management to prevent obesity. Graphical
- 5 February 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-12
Open AccessOpuntia cladode powders inhibit adipogenesis in 3 T3-F442A adipocytes and a high-fat-diet rat model by modifying metabolic parameters and favouring faecal fat excretion
Background: Obesity is a major public health concern worldwide. A sedentary life and a nutritional transition to processed foods and high-calorie diets are contributing factors to obesity. The demand for nutraceutical foods, such as herbal weight-loss products, which offer the potential to counteract obesity, has consequently increased. We hypothesised that Opuntia cladodes consumption could assist weight management in an obesity prevention context. Methods: This study was designed to explore the anti-adipogenic effects of lyophilised Opuntia cladode powders (OCP) in an in vitro cellular model for adipocyte differentiation and an in vivo high-fat-diet (HFD)-induced obesity rat model. Two OCP were tested, one from wild species O. streptacantha and the second from the most known species O. ficus-indica. Results: Pre-adipocytes 3 T3-F442A were treated by OCP during the differentiation process by insulin. OCP treatment impaired the differentiation in adipocytes, as supported by the decreased triglyceride content and a low glucose uptake, which remained comparable to that observed in undifferentiated controls, suggesting that an anti-adipogenic effect was exerted by OCP. Sprague–Dawley rats were fed with a normal or HFD, supplemented or not with OCP for 8 weeks. OCP treatment slightly reduced body weight gain, liver and abdominal fat weights, improved some obesity-related metabolic parameters and increased triglyceride excretion in the faeces. Taken together, these results showed that OCP might contribute to reduce adipogenesis and fat storage in a HFD context, notably by promoting the faecal excretion of fats. Conclusions: Opuntia cladodes may be used as a dietary supplement or potential therapeutic agent in diet-based therapies for weight management to prevent obesity. Graphical
- Open Access
Hepatocyte-specific deletion of Pparα promotes NASH in the context of obesity
Objectives: Peroxisome proliferator activated receptor α (PPARα) acts as a fatty acid sensor to orchestrate the transcription of genes coding for rate-limiting enzymes required for lipid oxidation in hepatocytes. Mice only lacking Pparα in hepatocytes spontaneously develop steatosis without obesity in aging. Altough steatosis is a benign condition it can develop into non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis and hepatocarcinoma. While NASH appears as a major public health concern worldwide, it remains an unmet medical need. Several drugs are being tested in clinical trials, including pharmacological agonists for the different PPAR isotypes. In current study, we investigated the role of hepatocyte PPARα in a preclinical model of steatosis. Methods/Results: We have investigated the role of hepatocyte PPARα in a preclinical model of steatosis using High Fat Diet (HFD) feeding as a model of obesity in C57BL/6J male Wild-Type mice ( WT ), in whole-body ( Pparα -/- ) mice and in mice lacking Pparα in hepatocyte ( Pparα hep-/- ). We provide evidence that Pparα deletion in hepatocytes promotes NASH in mice fed an HFD. This enhanced NASH susceptibility occurs without development of glucose intolerance. Moreover, our data reveal that non-hepatocytic PPARα activity predominantly contributes to the metabolic response to HFD. Conclusion: Taken together, our data support hepatocyte PPARα as being essential to the prevention of steatosis progression to NASH and that extra-hepatocyte PPARα activity contributes to whole-body lipid homeostasis. Highlights: Pparα deletion in hepatocytes promotes steatosis and inflammation in HFD-induced obesity Hepatocyte-specific deletion of Pparα dissociates NAFLD from glucose intolerance in HFD-induced obesity obesity Extrahepatic PPARα activity contributes to the metabolic response to HFD-induced obesity
Open AccessHepatocyte-specific deletion of Pparα promotes NASH in the context of obesity
Objectives: Peroxisome proliferator activated receptor α (PPARα) acts as a fatty acid sensor to orchestrate the transcription of genes coding for rate-limiting enzymes required for lipid oxidation in hepatocytes. Mice only lacking Pparα in hepatocytes spontaneously develop steatosis without obesity in aging. Altough steatosis is a benign condition it can develop into non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis and hepatocarcinoma. While NASH appears as a major public health concern worldwide, it remains an unmet medical need. Several drugs are being tested in clinical trials, including pharmacological agonists for the different PPAR isotypes. In current study, we investigated the role of hepatocyte PPARα in a preclinical model of steatosis. Methods/Results: We have investigated the role of hepatocyte PPARα in a preclinical model of steatosis using High Fat Diet (HFD) feeding as a model of obesity in C57BL/6J male Wild-Type mice ( WT ), in whole-body ( Pparα -/- ) mice and in mice lacking Pparα in hepatocyte ( Pparα hep-/- ). We provide evidence that Pparα deletion in hepatocytes promotes NASH in mice fed an HFD. This enhanced NASH susceptibility occurs without development of glucose intolerance. Moreover, our data reveal that non-hepatocytic PPARα activity predominantly contributes to the metabolic response to HFD. Conclusion: Taken together, our data support hepatocyte PPARα as being essential to the prevention of steatosis progression to NASH and that extra-hepatocyte PPARα activity contributes to whole-body lipid homeostasis. Highlights: Pparα deletion in hepatocytes promotes steatosis and inflammation in HFD-induced obesity Hepatocyte-specific deletion of Pparα dissociates NAFLD from glucose intolerance in HFD-induced obesity obesity Extrahepatic PPARα activity contributes to the metabolic response to HFD-induced obesity
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A29-A30
L’hépatokine FGF21 est unique dans sa réponse nutrionnelle au glucose et au jeûne dans le foie : interdépendence des facteurs de transcription ChREBP et PPARα
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A29-A30
L’hépatokine FGF21 est unique dans sa réponse nutrionnelle au glucose et au jeûne dans le foie : interdépendence des facteurs de transcription ChREBP et PPARα
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A1-A3
Identification des fonctions physiologiques de PPARbeta hépatocytaire : rôle possible dans le diabète de type 2
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A1-A3
Identification des fonctions physiologiques de PPARbeta hépatocytaire : rôle possible dans le diabète de type 2
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A92
Rôle spécifique de la PI3kinase alpha hépatocytaire : influence sur le diabète et la stéatose hépatique
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A92
Rôle spécifique de la PI3kinase alpha hépatocytaire : influence sur le diabète et la stéatose hépatique